[1] Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 1988. 72(2): 567-572. [2] Zouboulis CC. Retinoids--which dermatological indications will benefit in the near future? Skin Pharmacol Appl Skin Physiol, 2001. 14(5): 303-315. [3] Hurst RE. Bexarotene ligand pharmaceuticals. Curr Opin Investig Drugs, 2000. 1(4): 514-523. [4] Niles RM. The use of retinoids in the prevention and treatment of skin cancer. Expert Opin Pharmacother, 2002. 3(3): 299-303. [5] Chakravarti N, El-Naggar AK, Lotan R, et al. Expression of retinoid receptors in sebaceous cell carcinoma. J Cutan Pathol, 2006. 33(1): 10-17. [6] Chakravarti N, Lotan R, Diwan AH, et al. Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin Cancer Res, 2007. 13(16): 4817-4824. [7] Guruvayoorappan C, Pradeep CR, Kuttan G. 13-cis-retinoic acid induces apoptosis by modulating caspase-3, bcl-2, and p53 gene expression and regulates the activation of transcription factors in B16F-10 melanoma cells. J Environ Pathol Toxicol Oncol, 2008. 27(3): 197-207. [8] Mrass P, Rendl M, Mildner M, et al. Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Res, 2004. 64(18): 6542-6548. [9] Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res, 2002. 8(5): 1234-1240. [10] Wang A, Zeng R, Huang H. Retinoic acid and sodium butyrate as cell cycle regulators in the treatment of oral squamous carcinoma cells. Oncol Res, 2008. 17(4): 175-182. [11] Nieto-Rementeria N, Perez-Yarza G, Boyano MD, et al. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol, 2009. 160(3): 519-526. [12] Papoutsaki M, Lanza M, Marinari B, et al. The p73 gene is an anti-tumoral target of the RARbeta/gamma-selective retinoid tazarotene. J Invest Dermatol, 2004. 123(6): 1162-1168. [13] Rendl M, Ban J, Mrass P, et al. Caspase-14 expression by epidermal keratinocytes is regulated by retinoids in a differentiation-associated manner. J Invest Dermatol, 2002. 119(5): 1150-1155. [14] So PL, Lee K, Hebert J, et al. Topical tazarotene chemoprevention reduces Basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation. Cancer Res, 2004. 64(13): 4385-4389. [15] Duvic M, Ni X, Talpur R, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol, 2003. 121(4): 902-909. [16] Syed Z, Cheepala SB, Gill JN, et al. All-trans retinoic acid suppresses Stat3 signaling during skin carcinogenesis. Cancer Prev Res (Phila Pa), 2009. 2(10): 903-911. [17] Cheepala SB, Yin W, Syed Z, et al. Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer, 2009. 8: 27. [18] Niles RM. Vitamin A (retinoids) regulation of mouse melanoma growth and differentiation. J Nutr, 2003. 133(1): 282S-286S. [19] So PL, Fujimoto MA, Epstein EH, Jr. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol Cancer Ther, 2008. 7(5): 1275-1284.